by CytoPrevent | Jul 19, 2021 | News
The trilogue process with the European Council, Parliament and Commission under the Portuguese Presidency concludes today and there has been no discussion at all on the important legislative changes to the Carcinogens and Mutagens Directive (CMD), passed by the...
by CytoPrevent | Jul 6, 2021 | Videos
https://cytoprevent.eu/wp-content/uploads/2021/07/Highlighting-the-risks-of-Hazardous-Drugs-contamination-in-Oncology-Day-Units.mp4...
by CytoPrevent | Jun 15, 2021 | Board’s Position Papers
Paris, June 10th, 2021 CytoPrevent* Advisory Board proposals to update the CMD While the European Commission has just started the Trilog process to amend the Carcinogen and Mutagen Directive (CMD), CytoPrevent Advisory Board wishes to express some key concerns...
by CytoPrevent | May 15, 2021 | Board’s Position Papers
The need to use a more appropriate acronym for CSTDs for administration of cytotoxic drugs Proposal for including in the amendment of Directive 2004/37/EC on the protection of workers from the risks related to exposure to carcinogens or mutagens at work, a...
by CytoPrevent | Apr 21, 2021 | News, What’s new on CytoPrevent
SUMMARY OF STUDY To reinforce protection of workers from exposure to hazardous medicinal products, including cytotoxic medicinal products: an Independent Group to European Commission made a study with different proposals The study was implemented during the period...